Immunohistochemical prediction of brain metastases in patients with advanced breast cancer: the role of Rad51.

Authors :: Sosińska-Mielcarek K
Duchnowska R
Winczura P
Badzio A
Majewska H
Lakomy J
Pęksa R
Pieczyńska B
Radecka B
Dębska S
Biernat W
Jassem J
Source :: Breast (Edinburgh, Scotland) [Breast] 2013 Dec; Vol. 22 (6), pp. 1178-83. Date of Electronic Publication: 2013 Sep 20.
Publication Year :: 2013
Abstract: Background: There are no clinically useful biomarkers predictive of brain metastases (BM) in breast cancer. In this study, we investigated the correlation between expression of selected proteins in the primary tumor and the risk of BM in patients with metastatic breast cancer (MBC).<br />Methods: The study included 198 MBC patients (96 with and 102 without BM). Using tissue microarrays derived from the primary tumor, we assessed by immunohistochemical expression of ER, PR, HER2, Ki-67, CK5/6, EGFR, HER3, CXCR4, Rad51, E-cadherin, and claudin 3 and 4.<br />Results: Ki-67 ≥14% (hazard ratio [HR] 2.76; P < 0.001), cytoplasmic expression of Rad51 (HR 1.87; P = 0.014) and ER-negativity (HR 1.72; P = 0.029) were associated with increased risk of BM in the multivariate analysis. A three-biomarker profile including ER, Ki-67 and Rad51 vs. other subtypes combined yielded an HR of 4.43 (P < 0.001).<br />Conclusions: ER-negativity, cytoplasmic expression of Rad51 and high Ki-67 are associated with increased risk of BM.<br /> (Copyright © 2013 Elsevier Ltd. All rights reserved.)

Full Text Access

Tools